INTRODUCTION
Cardiovascular diseases are the biggest cause of deaths worldwide. Cardiovascular diseases include high blood pressure, coronary heart disease (CHD), cardiomyopathy, heart failure and stroke. In particular, CHD annually results in 502 000 deaths in USA, and more than 700 000 deaths in China (1, 2) . CHD is a common complex disorder, which can be caused by single gene or multifactorial conditions resulting from interactions between environmental and inherited risk factors (3) (4) (5) . Efforts to identify genetic determinants of CHD have been directed primarily on nuclear genomes (6) . Genome-wide association studies in the population of European and Asian ancestries have identified several genetic loci that are associated with the risk of CHD (7) (8) (9) (10) . Especially, a SNP, rs6903956 in C6orf105 on chromosome 6p24 is associated with susceptibility to CHD in the Chinese population (11) . However, the mitochondrial genetic determinant for the development of CHD remains poorly explored. Mitochondrial dysfunction has been implicated to contribute to a wide range of cardiovascular disorders such as † The first four authors had equally contributed to this work. * To whom correspondence should be addressed at: Department of Genetics, Zhejiang University, 866 Yuhangtang Road, Hangzhou, Zhejiang 310058, China. Tel: +86 57188206497; Fax: +86 57188982377; Email: gminxin88@zju.edu.cn or min-xin.guan@cchmc.org cardiomyopathy and hypertension (12) (13) (14) (15) . In particular, mutations in mitochondrial DNA (mtDNA) have been associated with hypertension (15, 16) . Of these, the 4291T.C mutation in the tRNA Ile gene has been associated with a cluster of metabolic defects, including hypertension, hypercholesterolemia and hypomagnesemia (17) . Furthermore, the tRNA Ile 4263A.G, tRNA Met 4435A.G mutations and the 4401A.G mutation in the junction of tRNA Met and tRNA Gln genes have been associated with hypertension in several Chinese pedigrees (18) (19) (20) .
To investigate whether mitochondrial genetic defects contribute to the pathogenesis of CHD, we have initiated a systematic and extended mutational screening of mtDNA in a large cohort of CHD subjects in the Chinese population. One four-generation Han Chinese family ( Fig. 1 ) with maternally transmitted CHD was ascertained at the Cardiac Clinic of Anzhen Hospital, Beijing, China. Thirteen of the 32 adult members in this family exhibited the variable severity and age-at-onset of CHD. Mutational analysis of their mitochondrial genomes identified the tRNA Thr 15927G.A mutation belonging to the Eastern Asian haplogroup B5 in this Chinese family (21) . This 15927G.A mutation is localized at the highly conserved base in the anticodon stem, corresponding to conventional position 42 of the tRNA Thr (22, 23) . Thus, it is anticipated that the 15927G.A mutation alters the structure and function of tRNA Thr , thereby causing the mitochondrial dysfunction necessary for the development of CHD. Functional significance of the 15927G.A mutation was further evaluated by examining the steady-state levels and aminoacylation capacities of mitochondrial tRNAs including tRNA Thr by using lymphoblastoid cell lines derived from five affected matrilineal relatives carrying the 15927G.A mutation and from three control individuals lacking the mtDNA mutation. These cell lines were further assessed for the effects of the 15927G.A mutation on mitochondrial protein synthesis, endogenous respiration and substrate-dependent respiration as well as the production of reactive oxygen species (ROS).
RESULTS

Clinical presentation
The proband (BJH15-III-7) developed CHD at the age of 40 years. He presented to the Cardiology Clinic of Anzhen Hospital for further clinical and biochemical evaluations at the age of 55 years. He was diagnosed as having ischemia (extent of CAD based on extent of angiographic coronary was narrowed .85%), hypertension (160/95 mm Hg) and hypercholesterolemia [total cholesterol (TC) ¼ 220 mg/dl and low-density lipoprotein cholesterol (LDL-C).160 mg/dl). He did not have other clinical abnormalities, including diabetes mellitus, vision and hearing impairments, and renal and neurological disorders. As shown in Figure 1 and Table 1 , a clinical and biochemical evaluation of other 31 members in this family revealed a high prevalence of CHD, hypertension and hyperlipidemia. Of other 12 matrilineal relatives, 7 members suffered from only CHD, 1 subject (III-6) had CHD with hypercholesterolemia and 1 individual (II-3) exhibited CHD with hypertension and hypercholesterolemia. All affected fathers with CHD, except the subject II-3 who married with the affected subject II-4, never transmitted the trait to their offsprings, whereas all affected mothers transmitted the trait to their offsprings. These features are the maternal transmissions of CHD, suggesting the mitochondrial involvement. In addition, the individual II-4, who was the wife of II-3 but not a sibling of II-2 an II-6, suffered from CHD at the age of 70 years. A corresponding mitochondrial DNA mutation by the subject II-4 would be introduced independently into the pedigree, causing CHD of subjects III-12 and III-13. Thus, the subjects II-4, III-12, III-13, IV-7 and IV-8 represented a different maternal pedigree.
Mutational analysis of mitochondrial genome
Southern blot analysis showed no evidence of mitochondrial DNA deletion or duplication among 32 members of this family (data not shown). We then performed a PCR amplification of fragments spanning their mitochondrial genomes and subsequent DNA sequence analysis in six matrilineal relatives (II-2, II-6, III-2, III-7, III-9 and IV-3) who were offsprings of I-2, and subject II-4 with two of her offsprings (III-12 and III-13). As shown in Supplementary Material, Table, these subjects carried the identical tRNA Thr 15927G.A mutation and distinct sets of polymorphisms (31 identical variants of each 43 variants between III-7 and III-12) belonging to the Eastern Asian haplogroup B5 on their maternal lineages (21, 24) . The 15927G.A mutation, as shown in Figure 2 , locates at the fourth base in the anticodon stem, corresponding to conventional position 42 of the tRNA Thr (22, 23) . A guanine at this position is a conserved base in sequenced threonine tRNA from bacteria to human mitochondria (22, 23) . It was anticipated that the 15927G.A mutation destabilizes a very conservative base pairing (28C-42G) on the anticodon stem of this tRNA Thr , thus causing a failure in tRNA metabolism. To determine whether the 15927G.A mutation is homoplasmy in cells, the fragments spanning the tRNA Thr gene were PCR amplified and subsequently digested with HpaII as the mutation disrupted the site for this restriction enzyme. As shown in Figure 2C , there was no detectable wild-type DNA in all-available matrilineal relatives, indicating that the 15927G.A mutation was present in homoplasmy in these matrilineal relatives but absent in other members in this family. In addition, allele frequency analysis showed that 3 of 80 genetically unrelated individuals with CHD and 2 of 262 Chinese control subjects who were free from CHD carried the 15927G.A mutation. Further genetic and clinical evaluation of 5 subjects (3 with CHD and 2 controls) carrying the mutation showed that only one Chinese family (BJH45) exhibited a maternal transmission of CHD (supplementary Material, Figure) . Entire mtDNA sequence analysis of proband BJH45 III-2 was shown in the supplementary Material, Table. Marked decrease in the levels of mitochondrial tRNA Thr To examine whether the 15927G.A mutation affects the tRNA Thr metabolism, we subjected mitochondrial RNAs from lymphoblastoid cell lines to Northern blots and hybridized them with digoxigenin (DIG)-labeled oligodeoxynucleotide probes for tRNA Thr and four other tRNAs (23, 25) . As shown in Figure 3A , the amount of tRNA Thr in five mutant cell lines carrying the 15927G.A mutation were markedly decreased, compared with those in three control cell lines lacking the mtDNA mutation. For comparison, the average levels of tRNA Thr in various control and mutant cell lines were normalized to the average levels in the same cell lines for tRNA Leu(CUN) , tRNA Lys , tRNA Ser(AGY) and tRNA
His
, respectively. As shown in Figure 3B , the average levels of tRNA Thr were examined by the use of electrophoresis in an acid polyacrylamide/urea gel system to separate uncharged tRNA species from the corresponding charged tRNA, electroblotting and hybridizing with above tRNA probes (26) . As shown in Figure 4 , the upper band represented the charged tRNA, and the lower band was uncharged tRNA. Electrophoretic patterns showed that either charged or uncharged tRNA Thr in cell lines carrying the 15927G.A mutation migrated much slower than those of cell lines lacking this mutation. However, there were no obvious differences in electrophoretic mobility of tRNA Leu(CUN) , tRNA Lys and tRNA Ser(AGY) between the cell lines carrying the 15927G.A mutation and cell lines lacking this mutation. Notably, the efficiencies of aminoacylated tRNA Thr in these mutant cell lines reflected 39% reduction, ranged from 35 to 43%, relative to the average control values (P ¼ 0.005). However, the levels of aminoacylation in tRNA Leu(CUN) , tRNA Lys and tRNA Ser(AGY) in mutant cell lines were comparable with those in the control cell lines.
Mitochondrial protein synthesis defect
To examine whether the failure in tRNA metabolism caused by the 15927G.A mutation impairs mitochondrial translation, cell lines derived from five affected matrilineal relatives carrying the 15927G.A mutation and three controls were labeled for 30 min with free regular DMEM medium in the presence of 100 mg/ml of emetine to inhibit cytosolic protein synthesis (27) . Figure 5A shows typical electrophoretic patterns of the mitochondrial translation products of the mutant and control cell lines. Patterns of the mtDNA-encoded polypeptides of the cells carrying the 15927G.A mutation were qualitatively identical to those of the control cells, in terms of electrophoretic mobility of the various polypeptides. However, cell lines carrying the 15927G.A mutation trended to a decrease in the total rate of labeling of the mitochondrial translation products relative to those of the control cell lines. Figure 5B shows a quantification of the results of a large number of labeling experiments and electrophoretic runs, which were carried out using Image-Quant program analysis of appropriate exposures of the fluorograms and normalization to data obtained for the 143B.TK -sample. In fact, the overall rates of labeling of the mitochondrial translation products in the cell lines derived from five affected individuals carrying the 15927G.A mutation ranged from 23 to 69%, with an average of 47% (P ¼ 0.005) relative to the mean value measured in the control cell lines.
Respiration deficiency
The endogenous respiration rates of cell lines derived from five affected individuals carrying the15927G.A mutation and three controls were measured by determining the O 2 consumption rate in intact cells, as described previously (28) . As shown in Figure 6A , the rate of total O 2 consumption in the cell lines derived from five affected individuals varied from 59 to 79%, with an average of 67% (P ¼ 0.001) relative to the mean value measured in the control cell lines.
To investigate which of the enzyme complexes of the respiratory chain was affected in the mutant cell lines, O 2 consumption measurements were carried out on digitonin-permeabilized cells, using different substrates and inhibitors (29) . As shown in Figure 6B , in the cell lines derived from five affected individuals, the rate of malate/glutamate-driven respiration, which depends on the activities of NADH: ubiquinone oxidoreductase (Complex I), ubiquinol -cytochrome c reductase (Complex III) and cytochrome c oxidase (Complex IV), but usually reflects the rate-limiting activity of Complex I, was very significantly decreased, relative to the average rate in the three control cell lines, by 54-77% (65% on the average; P ¼ 0.001). Similarly, the rate of succinate/glycerol-3-phosphate (G3P)-driven respiration, which depends on the activities of Complexes III and IV, but usually reflects the rate-limiting activity of Complex III, was significantly affected in the mutant cell lines, relative to the average rate in the control cell lines, by 62 -81% (70% on the average; P ¼ 0.0001). Furthermore, the rate of N,N,N ′ , N ′ -tetramethyl-p-phenylenediamine (TMPD)/ascorbate-driven respiration, which reflects the activity of Complex IV, exhibited a 63-76% reduction in Complex IV activity (69% on the average; P ¼ 0.001) in the mutant cell lines relative to the average rate in the control cell lines.
ROS production increases
To investigate whether the mitochondrial dysfunction increases the production of ROS, we measured the levels of the ROS generation in the vital cells derived from five affected matrilineal relatives carrying the 15927G.A mutation and three control individuals lacking the mutation using flow cytometry under normal and H 2 O 2 stimulation (30,31). Geometric mean intensity was recorded to measure the rate of ROS of each sample. The ratio of geometric mean intensity between unstimulated and stimulated with H 2 O 2 in each cell line was calculated to delineate the reaction upon increasing level of ROS under oxidative stress. As shown in Figure 7 , the levels of ROS generation in the lymphoblastoid cell lines derived from five affected individuals carrying the mtDNA mutation ranged from 117 and 123%, with an average 122% (P ¼ 0.0001) of the mean value measured in the control cell lines.
DISCUSSION
The present study provides the first direct evidence that mitochondrial genetic defect is associated with CHD. Adult (26), were expressed as percentages of the value for 143B.TK -in each gel, with error bars representing 2 SEMs. A total of three independent labeling experiments and three electrophoretic analyses of each labeled preparation were performed on cell lines. Graph details and symbols are explained in the legend to Figure 3. matrilineal relatives in one Chinese kindred exhibited a syndrome including CHD, hypertension and hyperlipidemia. In particular, CHD is transmitted on the maternal lineage with a pattern, indicating mitochondrial inheritance. mtDNA analysis of their maternal lineage identified a homoplasmy 15927G.A mutation at a highly conserved nucleotide (G42) of tRNA Thr , where the position is important for the stability and identity of tRNA (22) . The anticipated destabilization of base-pairing (28C-42G) by the 15927G.A mutation may affect secondary structure and function of this tRNA, as in the cases of tRNA Ile 4300A.G and tRNA Leu(UUR) 3273T.C mutations (32, 33) . The 15927G.A mutation changed the conformation of tRNA Thr , as suggested by slower electrophoretic mobility of mutated tRNA with respect to the wild-type molecule. However, the aminoacylation level of the tRNA Thr was not impaired, but the steady-state level of the tRNA was reduced 44% in lymphoblastoid cell lines derived from the Chinese control subjects carrying the 15927G.A mutation (23) . The mutant tRNA Thr may be metabolically less stable and more subject to degradation, thereby lowering the level of the tRNA, as in the case of 3243A.G mutation in the tRNA Leu(UUR) (25, 34) . However, an 70% decrease in the level of tRNA responsible for the significant respiratory defects was proposed as the threshold level that produces a clinical phenotype associated with a mitochondrial tRNA mutation (34, 35) . Thus, the relatively mild mitochondrial dysfunction caused by the 15927G.A mutation suggests that this mutation is by itself insufficient to produce a clinical phenotype (23) .
In the present investigation, the tRNA Thr carrying the 15927G.A mutation was charged to a lesser extent by the mitochondrial threonyl-tRNA synthetase, thereby altering aminoacylation. An 39% reduction in aminoacylated efficiency of tRNA Thr in mutant cells derived from this Chinese family with CHD apparently aggravates a failure in tRNA metabolism associated with the 15927G.A mutation, thereby yielding an 80% decrease in the steady-state level of tRNA Thr in mutant cell lines. This reduced level of tRNA is below the threshold level that leads to a clinical phenotype (34) (35) (36) . A shortage of tRNA Thr was responsible for 53% decrease in the rate of mitochondrial protein synthesis in the mutant cells, which is the proposed threshold level to support a normal respiratory phenotype (37) . The impaired mitochondrial protein synthesis apparently leads to defects in overall respiratory capacity or malate/ glutamate-promoted respiration or succinate/glycerol-3-phosphate-promoted respiration, or N,N,N ′ ,N ′ -tetramethyl-p-phenylenediamine/ascorbate-promoted respiration in mutant cells (25, 36) . Furthermore, the reduced mitochondrial protein synthesis may also result in the decrease in the activity of Complex V. Moreover, altered activities of Complexes I and III can lead to more electrons leakage from electron transport chain, and in turn, increase the generation of ROS (31, 38) . Here, an increase in ROS production was detected in cell lines derived from affected matrilineal relatives carrying the 15927G.A mutation. The increasing generation of ROS can damage to DNA, lipids, proteins and membranes. As a result, these biochemical defects can cause dysfunction or apoptosis in cardiac muscle cells, thereby producing the clinical phenotype. Therefore, these mitochondrial dysfunctions contribute to the pathogenesis of matrilineal CHD (12, (39) (40) (41) .
The homoplasmic nature of 15927G.A mutation in the tRNA Thr gene hints to mild nature of mutation, evidenced by a mild mitochondrial dysfunction observed in mutant cells (23) . These suggest that the 15927G.A mutation in the tRNA Thr gene is the inherited risk factors necessary for the development of CHD. The nuclear modifier genes, environmental and epigenetic factors, as well as personal life styles may also contribute to the development of CHD in these subjects carrying the mtDNA mutation (42, 43) . In particular, defects in nuclear modifier genes can worsen mitochondrial dysfunctions caused by the primary pathogenic mtDNA mutations, thereby modulating the phenotypic manifestation of primary mtDNA mutations (37, 44) . Indeed, genes encoding the mitochondrial tRNA synthetase or modifying enzyme can modulate the phenotypic variability of mitochondrial tRNA or 12S rRNA mutations (44, 45) . The coexistence of three tRNA mutations contributed to high penetrance of hypertension in two Chinese families (46) . Despite harboring the 15927G.A mutation belonging to haplogroup B5b (21, 23) , more drastic defects in tRNA metabolism in this family with CHD than those in other Chinese families strongly indicates the involvement of nuclear modifier genes required for tRNA metabolism in the development of CHD. Potential defects in nuclear genes may worsen mitochondrial dysfunction caused by the 15927G.A mutation, thereby producing the clinical phenotype. In particular, the tissue specificity of 15927G.A mutation in the tRNA Thr in the Chinese family is likely attributed to tissue-specific tRNA metabolism or the involvement of nuclear modifier genes.
In summary, our findings demonstrate that mitochondrial dysfunction caused by the tRNA Thr 15927G.A mutation is associated with CHD. The 15927G.A mutation altered tRNA metabolism, thereby impairing mitochondrial translation, respiration and increasing the production of ROS. Possible defects in nuclear modifiers may worsen the mitochondrial dysfunction caused by the 15927G.A mutation. Subsequently, mitochondrial dysfunctions and longstanding increase of ROS in cardiovascular cells may lead to the development of CHD. Thus, our findings may provide new insights into the understanding of pathophysiology and valuable information for management and treatment of CHD.
MATERIALS AND METHODS
Subjects
One four-generation Han Chinese family (BJH15) (Fig. 1) and 80 genetically unrelated subjects with CHD were ascertained at the Cardiac Clinics of Beijing Anzhen Hospital, Beijing, China. A total of 262 Han Chinese control subjects were obtained from a panel of unaffected Han Chinese individuals from the same area. Informed consent, blood samples and clinical evaluations were obtained from all participating family members, under protocols approved by the ethics committee of the Anzhen Hospital and Zhejiang University.
Risk factors assessment
Risk factors were considered as hypertension, hyperlipidemia, diabetes mellitus, cigarette smoking and family history for CHD. Blood pressure: a physician measured the systolic and diastolic blood pressures of subjects using a mercury column sphygmomanometer and a standard protocol. The first and the fifth Korotkoff sounds were taken as indicators of systolic and diastolic blood pressure, respectively. The average of three such systolic and diastolic blood pressure readings was taken as the examination blood pressure. Hypertension was defined according to the recommendation of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC VI) (47) 
Mutational analysis of mitochondrial genome
Genomic DNA was isolated from whole blood of all participants for this investigation using Puregene DNA Isolation Kits (Gentra Systems, Minneapolis, MN, USA). Southern blot analysis of mitochondrial genomes of 32 members of this Chinese family was carried out as detailed elsewhere (48) . The entire mitochondrial genomes of six matrilineal relatives (II-2, II-6, III-2, III-7, III-9 and IV-3) who were offsprings of I-2, and subject II-4 with two of her offsprings (III-12 and III-13) in this Chinese family were PCR amplified in 24 overlapping fragments by use of sets of the light-strand and the heavy strand oligonucleotide primers, as described elsewhere (49) . Each fragment was purified and subsequently analyzed by direct sequencing in an ABI 3700 automated DNA sequencer using the Big Dye Terminator Cycle sequencing reaction kit. The resultant sequence data were compared with the updated consensus Cambridge sequence (GenBank accession number: NC_012920) (24) . The presence and degree of the 15927G.A mutation for members of this family, 80 genetically unrelated individuals with CHD and control subjects were performed as detailed elsewhere (23) .
Cell cultures
Lymphoblastoid cell lines were immortalized by transformation with the Epstein-Barr virus, as described elsewhere (50) . Cell lines derived from five affected individuals (II-2, III-2, III-6, III-9 and IV-3) carrying the 15927G.A mutation and two married-in-controls (III-8 and IV-4) in this Chinese family, and a genetically unrelated control subject (A6) were grown in RPMI 1640 medium (Invitrogen), supplemented with 10% fetal bovine serum (FBS).
Mitochondrial tRNA northern analysis
Total mitochondrial RNA were obtained using TOTALLY RNATM kit (Ambion) from mitochondria isolated from lymphoblastoid cell lines ( 4.0 × 10 8 cells), as described previously (51) . Five micrograms of total mitochondrial RNA were electrophoresed through a 10% polyacrylamide/7 M urea gel in Tris-borate-EDTA buffer (TBE) (after heating the sample at 658C for 10 min), and then electroblotted onto a positively charged nylon membrane (Roche) for the hybridization analysis with oligodeoxynucleotide probes. For the detection of mitochondrial tRNAs, the following non-radioactive DIG-labeled oligodeoxynucleotides specific for tRNA Thr , tRNA Leu(CUN) , tRNA Lys , tRNA
His and tRNA Ser(AGY) were detailed elsewhere (23, 44) . DIG-labeled oligodeoxynucleotides were generated by using DIG oligonucleotide Tailing kit (Roche). The hybridization was carried out as detailed elsewhere (23, 36, 44) . Quantification of density in each band was made as detailed previously (23, 36, 44) .
Mitochondrial tRNA aminoacylation analysis
Total mitochondrial RNAs were isolated as above but under acid condition. The total mitochondrial RNA (2 mg) was electrophoresed at 48C through an acid 10% polyacrylamide/7 M urea gel in a 0.1 M sodium acetate (pH 5.0) to separate the charged and uncharged tRNA, as detailed elsewhere (23, 26) . Then RNAs were electro-blotted onto a positively charged membrane (Roche) and hybridized sequentially with the specific tRNA probes as above.
Analysis of mitochondrial protein synthesis
Pulse-labeling of the cell lines for 30 min with [ emetine, electrophoretic analysis of the translation products and quantification of radioactivity in the whole-electrophoretic patterns or in individual well-resolved bands were carried out as detailed previously (27) .
O 2 consumption measurements
Rates of O 2 consumption in intact cells were determined with a YSI 5300 oxygraph (Yellow Springs Instruments) on samples of 5 × 10 6 cells in 1.5 ml of a special DMEM medium lacking glucose, supplemented with 10% dialyzed FBS (28) . Polargraphic analysis of digitonin-permeabilized cells, using different respiratory substrates and inhibitors, to test the activity of the various respiratory complexes was carried out as detailed previously (29) .
ROS measurements
ROS measurements were performed following the procedures detailed elsewhere (30, 31) . Briefly, approximate 2 × 10 6 cells of each cell line were harvested, resuspended in PBS supplemented with 100 mM of 2 ′ ,7 ′ -dichlorodihydrofluorescein diacetate (DCFH-DA) and then incubated at 378C for 20 min. After washing with PBS twice, cells were resuspended in PBS in the presence of 2 mM freshly prepared H 2 O 2 and 2% FBS and then incubated at room temperature for another 5 min. Cells were further washed with PBS and resuspended with 1 ml of PBS with 0.5% paraformaldehyde. Samples with or without H 2 O 2 stimulation were analyzed by BD-LSR II flow cytometer system (Beckton Dickson, Inc.), with an excitation at 488 nm and emission at 529 nm. A total of 10 000 events were analyzed in each sample.
Statistical analysis
Statistical analysis was performed by the unpaired, two-tailed Student's t-test contained in Microsoft Office Excel (version 2007). P indicates the significance, according to the t-test, of the difference between mutant mean and control mean. Differences were considered significant at a P , 0.05.
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